Skip to main content
. 2023 Dec 17;11(9):2303366. doi: 10.1002/advs.202303366

Figure 1.

Figure 1

Construction and characterization of mosaic‐RBD nanoparticles. A) Schematic of nanoparticles components: MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 RBD were fused to the N terminal of the recombinant ferritin. B) SDS‐PAGE/commissa blue staining of nanoparticles. C) Negative‐stain electron micrographs of purified nanoparticle immunogens. Scale bar, 50 nm. D) Size distribution analysis of Mosaic‐RBD nanoparticles and recombinant Ferritin nanoparticles via DLS. E) Zeta‐potential distribution diagram for the Mosaic‐RBD nanoparticles and recombinant Ferritin nanoparticles. F) the binding assay of Mosaic‐RBD nanoparticles with the SARS‐CoV‐2, SARS‐CoV, and MERS‐CoV RBD‐specific monoclonal antibodies by ELISA.